Trend Analysis: GLP-1 drug expansion reshaping preventive care model beyond obesity management

Type: Trend Analysis · Industry: Salud y bienestar · Market: United States · Published: 2026-06-16

What's changing in your industry

  • GLP-1 drugs are expanding from weight loss into broad preventive care, shifting demand from quick fixes to long-term metabolic health.
  • The fitness industry is pivoting toward medically supervised GLP-1 support as the value of a plain gym membership shifts.
  • Access stays very unequal: only 2.3% of eligible adults have a prescription and rural areas lag cities by 37.5%.

What it means for your business

  • Your clients on these drugs lose weight but risk losing muscle, so coaching, strength work, and nutrition become the service they actually need.
  • There is an underserved market just outside big cities where almost no one is offering structured support.

3 actions to start today

  • Build a simple strength-and-protein program for clients using or considering GLP-1 medication, and say so in your marketing.
  • Partner with a local clinic or dietitian to refer clients both ways at no cost.
  • Target nearby rural or suburban clients who have far fewer wellness options than city dwellers.

1 number to benchmark yourself

Only 2.3% of eligible U.S. adults have a GLP-1 prescription, and rural areas trail cities by 37.5%. How underserved is your area?

Executive Summary

The U.S. Health & Wellness industry is undergoing a structural transformation driven by the rapid expansion of GLP-1 receptor agonist drugs beyond their original obesity indication into cardiovascular disease, chronic kidney disease, and emerging therapeutic frontiers including addiction medicine. With FDA approval of semaglutide for CKD in January 2025 and the American College of Cardiology elevating GLP-1s to first-line cardiovascular therapy in June 2025, the drug class is fundamentally reshaping the preventive care paradigm—shifting the industry's center of gravity from episodic sick-care to proactive metabolic health management.

This structural shift is creating cascading effects across every segment of the Health & Wellness ecosystem. Payers face urgent coverage policy decisions as the Medicare GLP-1 Bridge launches at $50/month copays (July 2026) while Medicaid coverage has narrowed to 13 states—a fragmentation that is deepening socioeconomic and geographic equity gaps. Health systems must redesign care coordination models to manage GLP-1 patients across cardiology, nephrology, endocrinology, and behavioral health simultaneously, at a time when the U.S. faces a projected shortage of 187,130 healthcare workers by 2037. Meanwhile, digital health platforms, pharma companies developing next-generation oral GLP-1 formulations, and retail health operators are all racing to capture value in this reconfiguring market.

The U.S. Health & Wellness market, valued at $988.67B in 2025 and projected to reach $1.545T by 2033, stands at an inflection point where GLP-1 expansion, AI-driven diagnostics, value-based care penetration, and equity imperatives will determine the competitive landscape for the next decade. Organizations that act now to build GLP-1-capable care infrastructure, invest in digital adherence tools, and develop equitable access strategies will define the winners in the preventive care economy of 2030.

Key Findings

  • GLP-1 drugs are expanding across five therapeutic segments—obesity, cardiovascular disease, chronic kidney disease, MASH, and addiction treatment—with the global GLP-1 market projected to reach $130.6B by 2033 at a 13.2% CAGR, but access remains severely inequitable: only 2.3% of eligible U.S. adults have received prescriptions and rural adoption lags urban areas by 37.5%.
  • FDA approved semaglutide for CKD in January 2025 (24% composite kidney outcomes risk reduction via FLOW trial), and the American College of Cardiology elevated GLP-1s to first-line cardiovascular therapy in June 2025, while Phase 3 trials for alcohol use disorder are targeting completion in April 2028—creating a 2-year window for payers and providers to prepare coverage and care models for addiction indications.
  • AI adoption in U.S. health systems reached 75% in 2026 (up from 59% in 2025), with digital health VC funding hitting $14.2B in 2025 (35% YoY growth)—yet a critical skills gap persists as 68% of healthcare leaders report insufficient confidence evaluating AI tools, and geographic AI adoption disparities range from 0% in some states to 49% in others.
  • The PBM reform mandated by the Consolidated Appropriations Act of 2026 (100% rebate pass-through, signed February 3, 2026) and the IRA drug pricing negotiations placing semaglutide/tirzepatide in Round 2 for 2027 will reshape the economics of GLP-1 distribution—enabling direct pharma-to-patient models (e.g., LillyDirect) while eliminating the PBM spread pricing that has historically inflated access barriers.
  • Three convergence vectors are redefining the industry's competitive boundaries: retail health (Amazon One Medical expanding with Nvidia/AWS AI partnerships; CVS Oak Street scaling to 300+ sites), health-fintech integration ($147B HSA market enabling pre-tax GLP-1 payments for 7M+ newly eligible Americans), and the fitness industry pivoting to medically supervised GLP-1 programs as gym membership value propositions fundamentally shift.

Report Contents

  1. 01 · Weak Signals & Emerging Patterns
  2. 02 · Macro Trends & Industry Megatrends
  3. 03 · Technology Adoption & Digital Health
  4. 04 · Consumer Evolution & Behavioral Shifts
  5. 05 · Business Model Innovation
  6. 06 · Sustainability & ESG
  7. 07 · Regulatory & Policy Shifts
  8. 08 · Talent & Workforce
  9. 09 · Investment & Capital Flows
  10. 10 · Digital Channels & Platforms
  11. 11 · Sector Convergence
  12. 12 · Future Scenarios & Projections
  13. 13 · Materialization Timeline
  14. 14 · Strategic Implications

Related reports

Sources

Access the full report

$29 USD/mo — Includes access to all reports for your industry.

Subscribe now